Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.

Practice changing standardization of lower extremity lymphedema quantitative measurements with integrated patient reported outcomes will likely refine and redefine the optimal risk-reduction strategies to diminish the devastating limb-related dysfunction and morbidity associated with treatment of gynecologic cancers. The National Cancer Institute (NCI), Division of Cancer Prevention brought together a diverse group of cancer treatment, therapy and patient reported outcomes experts to discuss the current state-of-the-science in lymphedema evaluation with the potential goal of incorporating new strategies for optimal evaluation of lymphedema in future developing gynecologic clinical trials. • NCI assembled cancer experts to discuss the current state-of-the-science of lymphedema evaluation in gynecologic cancers. • Standardization of lymphedema measurements and patient reported outcomes may redefine optimal treatment strategies. • The goal of the meeting was optimal evaluation of lymphedema in future developing multisite gynecologic clinical trials. [ABSTRACT FROM AUTHOR]